Which immunosuppressive agent used as induction therapy in renal transplantation binds CD25 on activated T lymphocytes and blocks interleukin-2 dependent clonal expansion?
- A Antithymocyte globulin
- B Mycophenolate mofetil
- C Basiliximab ✓
- D Alemtuzumab
Correct answer: C. Basiliximab
Explanation
Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of the interleukin-2 receptor (CD25) expressed on activated T cells, preventing IL-2 mediated proliferation. Antithymocyte globulin is a polyclonal preparation causing broad T-cell depletion, and alemtuzumab depletes CD52-bearing lymphocytes, so both work by cytodepletion rather than receptor blockade. Mycophenolate acts intracellularly on guanine synthesis and is maintenance therapy, not induction.
Reference: Schwartz's Principles of Surgery, 11th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.